Treating colorectal cancer in the biomarker era – what's next?
In an interview, Prof. Julien Taieb comments on the major advances from colorectal cancer research which are driving the development of molecular-based therapies
The evolving landscape of rare tumour molecular characterisation
Continued collaboration to identify new molecular targets and treatments can build on existing success
Encouraging results validate PARP7 and TGFβ1 as potential targets for immunotherapy
Safety and biomarker status data of the PARP7 inhibitor RBN-2397 and the IgG4 monoclonal antibody SRK-181 presented at the ESMO TAT Congress 2023
Liquid biopsy moving to early cancer detection: is it still early times?
Despite the promises shown by some innovative technologies in the studies presented, they will not replace existing diagnostic modalities soon
Are we getting closer to apply AI-based techniques in clinical practice?
AI technology is being tested across tumour types and with different purposes, with an emerging trend for adding value to whole slide image analyses for HER2 status
Pathogenic variants in HRR genes can be a risk factor for anthracycline-induced cardiotoxicity
A study presented at ESMO Congress 2022 highlights the need to identify predictors of anticancer drug toxicity as more complex treatments become available
Preclinical research offers promise of new CDK4/6 inhibitors
Positive in vitro and in vivo antitumour effects in breast and lung cancer models and in mismatch repair-driven cancer models
Predict the next evolutionary move of cancer: a feasible winning strategy?
Tumour evolution is one of the primary reasons for resistance to treatment and researchers are now learning how to use it to lead tumours down a dead end